Biomi Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 62.29%
- Profit Growth 80.16%
- Ebitda 51.53%
- Net Worth 124.19%
- Total Assets 47.71%
About Biomi Life Sciences
Biomi Life Sciences Private Limited (BLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 March 2016 (Eight years and 11 months 5 days old ). Its registered office is in Chandrapur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mamta Dwivedi and Prashant Dwivedi serve as directors at the Company.
Company Details
-
Location
Chandrapur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24296MH2016PTC274278
-
Company No.
274278
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Mar 2016
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Biomi Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mamta Dwivedi
|
Director | 12-Mar-2016 | Current |
|
Prashant Dwivedi
|
Director | 22-Mar-2022 | Current |
Financial Performance of Biomi Life Sciences.
Biomi Life Sciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 62.29% increase. The company also saw a substantial improvement in profitability, with a 80.16% increase in profit. The company's net worth Soared by an impressive increase of 124.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biomi Life Sciences?
In 2020, Biomi Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Premier Plant Services & Engineers Private LimitedMamta Dwivedi is a mutual person
-
Premier Universal Ventures Private LimitedMamta Dwivedi is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Biomi Life Sciences?
Biomi Life Sciences has a workforce of 8 employees as of Mar 20, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biomi Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biomi Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
